-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the marketing application for anituzumab (KN026), developed in cooperation with Jiangsu Corning Jerry Biopharmaceutical Co., Ltd., a subsidiary of the Company, and new adjuvant treatment of injectable docetaxel (albumin binding) (HB1801) independently developed by the Group has been accepted by the China Drug Administration (China Drug Administration) of the People's Republic of China and included in the priority review and approval process. The application is indicated for anitumab combined with docetaxel (albumin binding type) ± carboplatin as adjuvant treatment for early or locally advanced HER2-positive adult breast cancer.

Zhitongcaijing·08/04/2026 10:09:18
Listen to the news
According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the marketing application for anituzumab (KN026), developed in cooperation with Jiangsu Corning Jerry Biopharmaceutical Co., Ltd., a subsidiary of the Company, and new adjuvant treatment of injectable docetaxel (albumin binding) (HB1801) independently developed by the Group has been accepted by the China Drug Administration (China Drug Administration) of the People's Republic of China and included in the priority review and approval process. The application is indicated for anitumab combined with docetaxel (albumin binding type) ± carboplatin as adjuvant treatment for early or locally advanced HER2-positive adult breast cancer.